SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
20 Junho 2023 - 9:00AM
SEED Therapeutics (the “Company”), a BeyondSpring (NASDAQ: BYSI)
subsidiary and global research company focused on harnessing and
engineering “molecular glues,” a targeted protein degradation (TPD)
platform to attack previously believed undruggable targets, today
announced that it has appointed Jackson Tai to its Board of
Directors. Mr. Tai has most recently retired, or will soon retire,
as a Non-Executive Director of Eli Lilly (after 10 years), HSBC
(after 7 years), and Mastercard (after 15 years). He brings almost
50 years’ experience in finance, strategy, and risk governance to
the SEED Therapeutics Board.
“Jack’s substantial expertise in the realms of
finance, strategy, and risk governance is demonstrated through his
tenure as Vice Chairman and CEO of DBS Bank, one of the largest
financial institutions in Asia, as well as over 25 years as an
investment banker for the former J.P. Morgan & Co.
Incorporated, where he held senior management responsibilities,
including as head of Japanese Capital Markets in Tokyo and as
Senior Officer for Asia Pacific. With the ongoing success at SEED
Therapeutics, Mr. Tai’s background in operational management,
strategy, and in corporate governance will help SEED’s value
realization and corporate and risk management,” said Dr. Lan Huang,
SEED Therapeutics’ Chief Executive Officer.
Mr. Tai has served as Non-Executive Director at
several leading global companies, including Eli Lilly, HSBC (where
he was Chairman of the Risk Committee), and Mastercard. He
continues to serve as Board Member for Hong Kong Exchange listed
Wuxi Biologics (where he is Chairman of the Audit Committee). He
formerly served as Non-Executive Director for a number of
companies, including Canada Pension Plan Investment Board, The Bank
of China, Singapore Airlines, NYSE Euronext, and Royal Philips.
Mr. Tai also serves as a Board member of the
Metropolitan Opera, the New York Philharmonic, Rensselaer
Polytechnic Institute, as well as a member of the Harvard Business
School Asia-Pacific Advisory Board and the Council on Foreign
Relations. Mr. Tai obtained his Master of Business Administration
degree from Harvard University in 1974 and Bachelor of Science
degree from Rensselaer Polytechnic Institute in 1972.
“It is a privilege to join the SEED Therapeutics
Board and to work alongside our Co-Founding scientists and
visionaries who are recognized pioneers in the field of Targeted
Protein Degradation,” said Mr. Tai. “SEED Therapeutics’ seasoned
and experienced team is well-positioned to translate a breakthrough
platform to a pipeline of approved drugs for multiple unmet medical
needs. It’s truly exciting to see Management, the Board, and
Co-Founders to be so obsessed with SEED Therapeutics’ opportunity
to be First to Market and Best in Class.”
About SEED TherapeuticsSEED
Therapeutics is a global research company focused on harnessing and
engineering “molecular glues” in targeted protein degradation (TPD)
platform to attack previously believed undruggable targets. Backed
by a comprehensive intellectual property portfolio, SEED
Therapeutics' mission is to positively impact human health by
creating novel protein degradation therapeutics to treat various
severe diseases that currently have limited treatment options for
patients and their families. Through ongoing collaborations with
world-leading academic experts in the field, SEED Therapeutics is
establishing a growing pipeline of novel drug candidates on a path
to potential clinical and commercial success. Learn more by
visiting https://seedtherapeutics.com/.
About BeyondSpring BeyondSpring
(NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company
focused on developing innovative therapies to improve clinical
outcomes for patients with high unmet medical needs. The Company is
advancing its first-in-class lead asset, Plinabulin, as a direct
anti-cancer agent in various cancer indications and to prevent
chemotherapy-induced neutropenia. Its pipeline also includes three
preclinical immuno-oncology assets. Additionally, BeyondSpring’s
subsidiary, SEED Therapeutics, leverages a proprietary targeted
protein degradation (TPD) drug discovery platform and has an
initial R&D collaboration with Eli Lilly. Learn more by
visiting https://beyondspringpharma.com, and follow us on LinkedIn
and Twitter.
Investor Contact:IR@beyondspringpharma.com
Media Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024